Suggestions
Jesus del Valle
Head of Bayer R&D Stranger Things, CoFounder of AcceleRed
Jesus del Valle is a multifaceted professional with extensive experience in the pharmaceutical and digital health industries. He is currently the Co-Founder of AcceleRed, a company building project, and holds the position of Head of Bayer Pharma Business Disruption.12
Background and Education
Originally from Havana, Cuba, del Valle has a strong academic background in science. He graduated as a Physicist from the Technical University of Dresden and obtained his PhD in Biology from the Max Planck Institute / Free University in Berlin.1
Professional Experience
With over 20 years of experience in Life Sciences, del Valle has held various roles:
- Bayer: He started in IT roles within R&D and M&S departments. Currently, he leads the Stranger Things Team at Bayer Pharmaceuticals R&D.1
- Grants4Apps: In 2013, he founded this open innovation initiative at Bayer, which evolved into a digital health accelerator and coworking program.1
- AcceleRed: As a Co-Founder, del Valle is involved in building this company, which organizes online hackathons and volunteers for various initiatives.4
Initiatives and Community Involvement
Del Valle has been instrumental in creating and leading several initiatives:
- STEM4Health: He founded this global community, which now boasts 15,000 members, to foster networking among healthcare industry stakeholders.1
- AllThingsPharma: Through this initiative, he seeks opportunities for collaborations and investments in Biotech projects in academic and industrial sectors.1
Social Media Presence
Jesus del Valle maintains an active online presence:
- LinkedIn: His username is yeysus, where he frequently posts about his work and industry insights.23
- Twitter: He can be found at @yeysus, where he describes himself as involved in Business Disruption at Bayer Pharma, AcceleRed, and various other initiatives.5
Del Valle's passion lies in bridging the gap between startup culture and technological knowledge with Bayer's experience, contributing to innovation in the pharmaceutical and digital health sectors.1
